PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2023
CASE
AUTH/3744/2/23 Boehringer Ingelheim ⭐ Case of the Week

AUTH/3744/2/23: Boehringer Ingelheimβ€”Broken prescribing information link on promotional website (Pradaxa/Praxbind)

A third-party promotional webpage had a non-functioning single-click PI link for Pradaxa/Praxbind for ~3 weeks. An earlier email alert to medical information…

2021
CASE
Roche Products

Roche: patient organisation website grantβ€”support not clear from the outset and grant agreement missing required transparency wording

Roche funded a patient organisation website update. PMCPA found the declaration of support wasn’t apparent from the start and the written grant…

2023
CASE
AUTH/3732/1/23 Novartis Pharmaceuticals UK

Novartis: Tasigna GB prescribing information showed NI marketing authorisation numbers (AUTH/3732/1/23)

A Novartis HCP website link to Tasigna β€œGreat Britain Prescribing Information” mistakenly displayed Northern Ireland marketing authorisation numbers. The Panel ruled a…

2023
CASE
AUTH/3753/3/23 Novavax UK

Novavax: Nuvaxovid ad seen without HCP confirmation on P3 Pharmacy website (AUTH/3753/3/23) – No breach

Complaint that a Nuvaxovid (POM) web ad appeared without HCP confirmation. Panel found P3 Pharmacy could be an independently produced HCP journal…

2023
CASE
AUTH/3751/3/23 Otsuka

Otsuka: Jinarc training portal wording and aRMM guide omission found misleading (AUTH/3751/3/23)

PMCPA found Otsuka’s Jinarc training portal gave contradictory messages about enrolment being required to prescribe, and an HCP educational guide omitted a…

2023
CASE
AUTH/3729/1/23 AstraZeneca ⭐ Case of the Week

AstraZeneca: promotional meeting misclassified and LinkedIn engagement led to pre-authorisation promotion and public advertising findings (AUTH/3729/1/23)

Six amalgamated complaints. Breaches found for a UK β€œthink tank” meeting (uncertified promotional content; β€˜cure’ implication) and LinkedIn likes/reposts (pre-authorisation promotion; public…

2024
CASE
AUTH/3875/02/24 GlaxoSmithKline

AUTH/3875/02/24: LinkedIn post mentioning Arexvy in financial results video (No breach)

GSK was complained about after a senior leader mentioned β€œArexvy” once in a LinkedIn video tied to FY2023 results. Panel found the…

2023
CASE
AUTH/3783/6/23 Moderna

Moderna: Madrid β€œadvisory board” ruled promotional; unlicensed/off-SPC vaccine content and inducement concerns (AUTH/3783/6/23)

Global advisory board in Madrid with a UK HCP was ruled not genuine. Panel found promotion of an investigational RSV vaccine and…

2023
CASE
AUTH/3855/11/23 Bayer

AUTH/3855/11/23: Complainant v Bayer (Google search access to HCP portal PDFs) – No breach

Complaint alleged Google searches allowed public access to Bayer β€œadvertisements” for medicines. Panel found documents were non-promotional or appropriately gated for HCPs.…

2023
CASE
AUTH/3826/09/23 GlaxoSmithKline

AUTH/3826/09/23: Ex-contractor v GSK β€” allegations of falsified/duplicated rep calls in CRM (No breach)

Ex-contractor alleged GSK hospital reps duplicated/falsified CRM call records and management knew. Referee said call frequency aspect was in scope, but Panel…

2024
CASE
AUTH/3917/6/24 Jazz ⭐ Case of the Week

Jazz Pharmaceuticals: Epidyolex HCP videos ruled misleading due to omitted hepatic contraindication and dose adjustment/discontinuation guidance (AUTH/3917/6/24)

Two Jazz-funded promotional/educational HCP videos for Epidyolex omitted key SPC liver contraindication and management guidance for concomitant valproate use. PMCPA found misleading…

2021
CASE
AstraZeneca

AstraZeneca corporate medicines webpage: inaccurate black triangle status breached Clause 26.2

A clinician complained that AstraZeneca’s public corporate medicines list showed incorrect/missing black triangle symbols and omitted Imjudo. The Panel found a breach…

2007
CASE
AUTH/2065/11/07 Teva

Teva: Representative call rates and bonus-linked activity targets (AUTH/2065/11/07 & AUTH/2066/11/07)

Two anonymous Teva representatives alleged excessive call-rate targets and bonus-linked activity created indirect pressure to breach the Code. The Panel found briefing/instructions…

2008
CASE
Meda Pharmaceuticals ⭐ Case of the Week

Meda Pharmaceuticals: concerns about call/contact rate expectations and alleged off-licence promotion of Aldara

An anonymous representative alleged pressure to promote Aldara off-licence and raised concerns about call-rate targets and a GP letter. The Panel ruled…

2008
CASE
AUTH/2152/8/08 Sanofi

AUTH/2152/8/08: Novo Nordisk v Sanofi-Aventis – Promotion of Lantus (mailer and leavepieces)

Complaint about Lantus promotional materials. Panel ruled multiple presentations of comparative dosing/weight data were misleading due to context and incomplete disclosure, breaching…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training